Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-07-15
1998-03-31
Degen, Nancy
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
422 28, 422 30, 422 32, 435236, 435238, 514 8, 514 12, 530364, 530380, 5303901, 530416, 530427, 530830, A61K 3514, C07K 14475, C12N 706, A61L 216
Patent
active
057338850
ABSTRACT:
In a method of producing a virus-safe biological preparation by heating while preserving a least 50% of its biologic activity, a biologially compatible tenside is added to the preparation before heating and heating is carried out in the presence of the same, whereupon the tenside, preferably, is eliminated.
REFERENCES:
patent: 4297344 (1981-10-01), Schwinn et al.
patent: 4379085 (1983-04-01), Williams
patent: 4404187 (1983-09-01), Schwinn et al.
patent: 4405603 (1983-09-01), Schwinn et al.
patent: 4440679 (1984-04-01), Fernandes et al.
patent: 4585654 (1986-04-01), Landaburn
patent: 4673733 (1987-06-01), Chandra et al.
patent: 4814435 (1989-03-01), Schwartz et al.
patent: 4857320 (1989-08-01), Wither
patent: 4923815 (1990-05-01), Tanaka et al.
patent: 5118794 (1992-06-01), Grangeorge et al.
patent: 5132406 (1992-07-01), Uemora et al.
patent: 5143838 (1992-09-01), Kraus et al.
patent: 5151499 (1992-09-01), Kameyaura et al.
patent: 5371195 (1994-12-01), Grangeorge et al.
patent: 5410022 (1995-04-01), Eible et al.
patent: 5610147 (1997-03-01), Seelich
patent: 5639730 (1997-06-01), Eibl et al.
Hartert, H., "Thombosis and Bleeding Disorders", Academic Press, New York pp. 70-76 (1971).
Seelich, T., "Fibrinogen, Fibrin and Fibrin Glue, Side Effects of Therapy with Clotting Factor Concentrates", FK. Schattauer Verlag, Stuttgart, New York pp. 199-208 (1980).
Suomela, H., "Preparation and Properties of a Therapeutic Factor IX Concentrate", Vox Sanguinis, Journal of Blood Transfusion, Immunohaemotology and Immunopathology, vol. 33 pp. 37-50 (1977).
Clemens, R., "Wie Virussicher Sind Blut und Plasmaderivate?", Z. Allg. Med. 65, pp. 429-433 (1989).
Rubinstein, D.B., M.D., "Inability of Solvent-Detergent (S-D) Treated Factor VIII Concentrate to Inactivate Parvoviruses . . . ", American Journal of Hematology 35:142 (1990).
Prince, A.M. "The Development of Virus-Free Labile Blood Derivatives", Eur. J. Epidemiol., pp. 103-118 (Jun., 1987).
Chemical Abstracts, vol. 111, No. 22, 201439j, Nov. 27, 1989.
Chemical Abstracts, vol. 114, No. 5, 39082a, Feb. 4, 1991.
Rozenberg, XII International Congress on Blood Transfusion Abstracts, Moscow, pp. 473-475 (Aug. 17-23, 1969).
Chemical Abstracts, Pharmaceuticals, vol. 84, No. 16, 111640n, Apr. 19, 1976.
Commission of the European Communities, "Ad Hoc Working Party on Biotechnology/Pharmacy" 111/8115/89-EN Final, pp. 1-15.
Mannucci, P.M. et al., "Low Risk of Viral Infection After Adminstration of Vapor-Heated Factor VIII Concentrate", Transfusion, vol. 32, pp. 134-138 (1992).
Muller, W., "New Ion Exchangers for the Chromatography of Biopolymers", Journal of Chromatography, 510, pp. 133nn-140 (1990).
Signa Catalog (1992) p. 1470.
Eibl Johann
Hummel Gabriela
Redl Gerda
Seelich Thomas
Turecek Peter
Degen Nancy
Immuno Aktiengesellschaft
LandOfFree
Method of producing a virus-safe biological preparation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of producing a virus-safe biological preparation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of producing a virus-safe biological preparation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-51998